ABC | Volume 110, Nº3, March 2018

Short Editorial Costa e Hajjar What is the Role of Two-Dimensional Speckle Tracking Echocardiography in the Diagnosis and Management of Anthracycline-Induced Cardiotoxicity? Arq Bras Cardiol. 2018; 110(3):229-230 1. InstitutoNacional de Câncer Jos Alencar Gomes da Silva (INCA). Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro; 2017. 2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. Erratum in: CA Cancer J Clin. 2012;62(5):348. 3. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al; British Childhood Cancer Survivor Study Steering Group. Long-term cause-specific mortality among survivors of childhood cancer. JAMA . 2010;304(2):172-9. 4. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic reviewandmeta-analysisofrandomizedcontrolledtrials.BMCCancer.2010 Jun 29;10:337. 5. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Fabrizio V, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-8. 6. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M,et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high- risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81. 7. BoschX,RoviraM,SitgesM,DomènechA,Ortiz-P rez JT,deCaraltTM,etal. Enalaprilandcarvedilolforpreventingchemotherapy-induced leftventricular systolicdysfunction inpatientswithmalignanthemopathies:theOVERCOME trial(preventiOnof leftVentriculardysfunctionwithEnalaprilandcaRvedilol in patientssubmittedto intensiveChemOtherapyforthetreatmentofMalignant hEmopathies). J AmColl Cardiol. 2013;61(23):2355-62. 8. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, FagerlandMW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinicaltrialofcandesartanandmetoprolol.EurHeartJ.2016;37(21):1671-80. 9. Kang Y, Xiao F, Chen H, Wang W, Shen L, Zhao H, et al. Subclinical Anthracycline-Induced Cardiotoxicity in the Long-Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis. Arq Bras Cardiol. 2018; 110(3):219-228. 10. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. 11. Yu W, Li SN, Chan GC, Ha SY, Wong SJ, Cheung YF. Transmural strain and rotation gradient in survivors of childhood cancers. Eur Heart J Cardiovasc Imaging 2013;14(2):175-82. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 230